To explore the mode and effect of combined treatment strategy as second-line and subsequent treatment of GC, we performed the present study to evaluate the efficacy and safety of chemotherapy combined with a PD-1 antibody (sintilimab) and VEGFR2 inhibitor (apatinib). Here, KDR is linked to gastric cancer.